Interleukin-27 gene delivery for modifying malignant interactions between prostate tumor and bone

Olga Cain, Jayne Ellis, Sangram Parelkar, Delphine Chan-Seng, Todd Emrick, Jingna Wei, Igor Patrikeev, Massoud Motamedi, Marxa L. Figueiredo

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

We have examined the role of a novel cytokine, interleukin-27 (IL-27), in mediating interactions between prostate cancer and bone. IL-27 is the most recently characterized member of the family of heterodimeric IL-12-related cytokines and has shown promise in halting tumor growth and mediating tumor regression in several cancer models, including prostate cancer. Prostate cancer is frequently associated with metastases to the bone, where the tumor induces a vicious cycle of communication with osteoblasts and osteoclasts to induce bone lesions, which are a significant cause of pain and skeletal-related events for patients, including a high fracture risk. We describe our findings in the effects of IL-27 gene delivery on prostate cancer cells, osteoblasts, and osteoclasts at different stages of differentiation. We applied the IL-27 gene delivery protocol in vivo utilizing sonoporation (sonodelivery) with the goal of treating and reducing the growth of prostate cancer at a bone metastatic site in vivo. We used a new model of immune-competent prostate adenocarcinoma and characterized the tumor growth reduction, gene expression, and effector cellular profiles. Our results suggest that IL-27 can be effective in reducing tumor growth, can help normalize bone structure, and can promote enhanced accumulation of effector cells in prostate tumors. These results are promising, because they are relevant to developing a novel IL-27-based strategy that can treat both the tumor and the bone, by using this simple and effective sonodelivery method for treating prostate tumor bone metastases.

Original languageEnglish (US)
Pages (from-to)970-981
Number of pages12
JournalHuman Gene Therapy
Volume24
Issue number12
DOIs
StatePublished - Dec 1 2013

Fingerprint

Interleukin-27
Prostate
Bone and Bones
Prostatic Neoplasms
Genes
Neoplasms
Osteoclasts
Growth
Osteoblasts
Cytokines
Neoplasm Metastasis
Bone Neoplasms
Interleukin-12
Adenocarcinoma
Communication

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Cain, O., Ellis, J., Parelkar, S., Chan-Seng, D., Emrick, T., Wei, J., ... Figueiredo, M. L. (2013). Interleukin-27 gene delivery for modifying malignant interactions between prostate tumor and bone. Human Gene Therapy, 24(12), 970-981. https://doi.org/10.1089/hum.2013.091

Interleukin-27 gene delivery for modifying malignant interactions between prostate tumor and bone. / Cain, Olga; Ellis, Jayne; Parelkar, Sangram; Chan-Seng, Delphine; Emrick, Todd; Wei, Jingna; Patrikeev, Igor; Motamedi, Massoud; Figueiredo, Marxa L.

In: Human Gene Therapy, Vol. 24, No. 12, 01.12.2013, p. 970-981.

Research output: Contribution to journalArticle

Cain, O, Ellis, J, Parelkar, S, Chan-Seng, D, Emrick, T, Wei, J, Patrikeev, I, Motamedi, M & Figueiredo, ML 2013, 'Interleukin-27 gene delivery for modifying malignant interactions between prostate tumor and bone', Human Gene Therapy, vol. 24, no. 12, pp. 970-981. https://doi.org/10.1089/hum.2013.091
Cain, Olga ; Ellis, Jayne ; Parelkar, Sangram ; Chan-Seng, Delphine ; Emrick, Todd ; Wei, Jingna ; Patrikeev, Igor ; Motamedi, Massoud ; Figueiredo, Marxa L. / Interleukin-27 gene delivery for modifying malignant interactions between prostate tumor and bone. In: Human Gene Therapy. 2013 ; Vol. 24, No. 12. pp. 970-981.
@article{fe8d33b5071f4f4281f48dde9e1de433,
title = "Interleukin-27 gene delivery for modifying malignant interactions between prostate tumor and bone",
abstract = "We have examined the role of a novel cytokine, interleukin-27 (IL-27), in mediating interactions between prostate cancer and bone. IL-27 is the most recently characterized member of the family of heterodimeric IL-12-related cytokines and has shown promise in halting tumor growth and mediating tumor regression in several cancer models, including prostate cancer. Prostate cancer is frequently associated with metastases to the bone, where the tumor induces a vicious cycle of communication with osteoblasts and osteoclasts to induce bone lesions, which are a significant cause of pain and skeletal-related events for patients, including a high fracture risk. We describe our findings in the effects of IL-27 gene delivery on prostate cancer cells, osteoblasts, and osteoclasts at different stages of differentiation. We applied the IL-27 gene delivery protocol in vivo utilizing sonoporation (sonodelivery) with the goal of treating and reducing the growth of prostate cancer at a bone metastatic site in vivo. We used a new model of immune-competent prostate adenocarcinoma and characterized the tumor growth reduction, gene expression, and effector cellular profiles. Our results suggest that IL-27 can be effective in reducing tumor growth, can help normalize bone structure, and can promote enhanced accumulation of effector cells in prostate tumors. These results are promising, because they are relevant to developing a novel IL-27-based strategy that can treat both the tumor and the bone, by using this simple and effective sonodelivery method for treating prostate tumor bone metastases.",
author = "Olga Cain and Jayne Ellis and Sangram Parelkar and Delphine Chan-Seng and Todd Emrick and Jingna Wei and Igor Patrikeev and Massoud Motamedi and Figueiredo, {Marxa L.}",
year = "2013",
month = "12",
day = "1",
doi = "10.1089/hum.2013.091",
language = "English (US)",
volume = "24",
pages = "970--981",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "12",

}

TY - JOUR

T1 - Interleukin-27 gene delivery for modifying malignant interactions between prostate tumor and bone

AU - Cain, Olga

AU - Ellis, Jayne

AU - Parelkar, Sangram

AU - Chan-Seng, Delphine

AU - Emrick, Todd

AU - Wei, Jingna

AU - Patrikeev, Igor

AU - Motamedi, Massoud

AU - Figueiredo, Marxa L.

PY - 2013/12/1

Y1 - 2013/12/1

N2 - We have examined the role of a novel cytokine, interleukin-27 (IL-27), in mediating interactions between prostate cancer and bone. IL-27 is the most recently characterized member of the family of heterodimeric IL-12-related cytokines and has shown promise in halting tumor growth and mediating tumor regression in several cancer models, including prostate cancer. Prostate cancer is frequently associated with metastases to the bone, where the tumor induces a vicious cycle of communication with osteoblasts and osteoclasts to induce bone lesions, which are a significant cause of pain and skeletal-related events for patients, including a high fracture risk. We describe our findings in the effects of IL-27 gene delivery on prostate cancer cells, osteoblasts, and osteoclasts at different stages of differentiation. We applied the IL-27 gene delivery protocol in vivo utilizing sonoporation (sonodelivery) with the goal of treating and reducing the growth of prostate cancer at a bone metastatic site in vivo. We used a new model of immune-competent prostate adenocarcinoma and characterized the tumor growth reduction, gene expression, and effector cellular profiles. Our results suggest that IL-27 can be effective in reducing tumor growth, can help normalize bone structure, and can promote enhanced accumulation of effector cells in prostate tumors. These results are promising, because they are relevant to developing a novel IL-27-based strategy that can treat both the tumor and the bone, by using this simple and effective sonodelivery method for treating prostate tumor bone metastases.

AB - We have examined the role of a novel cytokine, interleukin-27 (IL-27), in mediating interactions between prostate cancer and bone. IL-27 is the most recently characterized member of the family of heterodimeric IL-12-related cytokines and has shown promise in halting tumor growth and mediating tumor regression in several cancer models, including prostate cancer. Prostate cancer is frequently associated with metastases to the bone, where the tumor induces a vicious cycle of communication with osteoblasts and osteoclasts to induce bone lesions, which are a significant cause of pain and skeletal-related events for patients, including a high fracture risk. We describe our findings in the effects of IL-27 gene delivery on prostate cancer cells, osteoblasts, and osteoclasts at different stages of differentiation. We applied the IL-27 gene delivery protocol in vivo utilizing sonoporation (sonodelivery) with the goal of treating and reducing the growth of prostate cancer at a bone metastatic site in vivo. We used a new model of immune-competent prostate adenocarcinoma and characterized the tumor growth reduction, gene expression, and effector cellular profiles. Our results suggest that IL-27 can be effective in reducing tumor growth, can help normalize bone structure, and can promote enhanced accumulation of effector cells in prostate tumors. These results are promising, because they are relevant to developing a novel IL-27-based strategy that can treat both the tumor and the bone, by using this simple and effective sonodelivery method for treating prostate tumor bone metastases.

UR - http://www.scopus.com/inward/record.url?scp=84890501693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890501693&partnerID=8YFLogxK

U2 - 10.1089/hum.2013.091

DO - 10.1089/hum.2013.091

M3 - Article

VL - 24

SP - 970

EP - 981

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 12

ER -